Literature DB >> 2233523

Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia.

O B Eden1, M P Shaw, J S Lilleyman, S Richards.   

Abstract

Seven hundred fifty-eight unselected children entered into the United Kingdom Medical Research Council acute lymphoblastic leukaemia UKALL VIII Study and Trial were studied for differences in early treatment-related toxicity according to the type of intramuscular L-asparaginase received. Two hundred seventy-five received a product obtained from Escherichia coli and 483 the enzyme from Erwinia chrysanthemi. The E. coli patients had a significantly higher incidence of neurotoxicity, pancreatitis, and life-threatening sepsis (4%, 2%, and 20%, respectively) when compared with the Erwinia group (2%, 0%, and 18%). Severe hypersensitivity was seen in one patient from both groups and the incidence of glucose intolerance was not significantly different. These findings indicate that E. coli asparaginase may be more toxic. With a minimum follow up of 4 1/2 years there is no evidence that either product has made a significantly different contribution to disease-free survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233523     DOI: 10.1002/mpo.2950180612

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  11 in total

Review 1.  Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years.

Authors:  J Lilleyman
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

3.  L-Asparaginase from Erwinia carotovora: insights about its stability and activity.

Authors:  Marcele Faret; Stephanie Bath de Morais; Nilson Ivo Tonin Zanchin; Tatiana de Arruda Campos Brasil de Souza
Journal:  Mol Biol Rep       Date:  2018-11-16       Impact factor: 2.316

Review 4.  Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining.

Authors:  Paul S Gaynon
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 5.  L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Authors:  Rob Pieters; Stephen P Hunger; Joachim Boos; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; Ching-Hon Pui
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.

Authors:  Z B Moola; M D Scawen; T Atkinson; D J Nicholls
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

Review 7.  An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.

Authors:  V Saha; T Eden
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

8.  HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.

Authors:  Christian A Fernandez; Colton Smith; Wenjian Yang; Mihir Daté; Donald Bashford; Eric Larsen; W Paul Bowman; Chengcheng Liu; Laura B Ramsey; Tamara Chang; Victoria Turner; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Suna Onengut-Gumuscu; Wei-Min Chen; Patrick Concannon; Stephen S Rich; Paul Scheet; Sima Jeha; Ching-Hon Pui; William E Evans; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2014-06-26       Impact factor: 22.113

9.  Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.

Authors:  C Mitchell; S Richards; C J Harrison; T Eden
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

10.  Purification, characterization, cytotoxicity and anticancer activities of L-asparaginase, anti-colon cancer protein, from the newly isolated alkaliphilic Streptomyces fradiae NEAE-82.

Authors:  Noura El-Ahmady El-Naggar; Sahar F Deraz; Hoda M Soliman; Nehal M El-Deeb; Sara M El-Ewasy
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.